관련근거
1.한국 천식진료지침 2021, 대한천식알레르기학회
2.천식진료지침 2022 5차 개정, 대한결핵 및 호흡기학회
3.GINA Guidelines (2024), Global Strategy for Asthma Management and Prevention (2023 Update)
4.Lee E, et al. Increasing prevalence and mortality of asthma with age in Korea, 2002-2015: a nationwide, population-based study. Allergy Asthma Immunol Res 2020;12(3):467-84.
5.Shim, Ji-Su, et al. "Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea." World Allergy Organization Journal 15.12 (2022): 100720.
6.Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry. Chest 2020;157(4):790-804.
7.Kim et al, Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry. Allergy Asthma Immunology Research. 2019;11(1):e10.
8.Rhee, Chin Kook, et al. "Effect of dupilumab in Korean patients with uncontrolled moderate-to-severe asthma: a LIBERTY ASTHMA QUEST sub-analysis." Allergy Asthma Immunology Research 2022 Mar;14(2):182-195
9.Hong et al, Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(5):1939-1947.e7
10.Kim, Sang-Heon, et al. "Perceptions of severe asthma and asthma-COPD overlap syndrome among specialists: a questionnaire survey." Allergy Asthma Immunology Research 10.3 (2018): 225-235.
11.Wechsler et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med 2022;10:11-25.
12.M. Castro, et al. Dupilumab Efficacy and Safety in Moderate to-Severe Uncontrolled Asthma. N Engl J Med 2018;378:2486-96.
13.Klaus et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med 2018;378:2475-85.
14.Wechsler et al. "Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE." Presented at the 30th International Congress of the European Respiratory Society (ERS); Virtual Congress; September. Vol. 7. 2020.
15.Akenroye et al. "Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis." Journal of Allergy and Clinical Immunology 150.5 (2022): 1097-1105.
16.Tohda et al. "Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan." Journal of Asthma 59.11 (2022): 2162-2173.
17.Rabe et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018;378:2475-85.
18.Akenroye et al. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol 2023;151:1269-76.
19.의약품 품목허가 보고서_듀피젠트프리필드펜200밀리그램 (2021)
20.의약품 품목허가 보고서_듀피젠트프리필드펜300밀리그램 (2021)